{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:09:25Z","timestamp":1785208165380,"version":"3.55.0"},"reference-count":50,"publisher":"Akademiai Kiado Zrt.","issue":"25","license":[{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,6,20]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> A neurodegenerat\u00edv betegs\u00e9gek k\u00f6z\u00f6tt az Alzheimer-k\u00f3r\n                    a leggyakoribb k\u00f3rforma. Morbidit\u00e1sa \u00e9s mortalit\u00e1sa vil\u00e1gszerte egyre gyorsabb\n                    \u00fctemben n\u00f6vekszik, ez\u00e1ltal szoci\u00e1lis \u00e9s gazdas\u00e1gi hat\u00e1sa is folyamatosan\n                    fokoz\u00f3d\u00f3 terhet jelent a t\u00e1rsadalomra. Az elm\u00falt n\u00e9h\u00e1ny \u00e9vtizedben jelent\u0151s\n                    el\u0151rel\u00e9p\u00e9s t\u00f6rt\u00e9nt az Alzheimer-k\u00f3r megismer\u00e9s\u00e9ben, sz\u00e1mos biomarker t\u00e1mogatja a\n                    diagn\u00f3zis fel\u00e1ll\u00edt\u00e1s\u00e1t, t\u00fcneti ter\u00e1pi\u00e1t szolg\u00e1l\u00f3 gy\u00f3gyszerek ker\u00fcltek\n                    bevezet\u00e9sre. Az Alzheimer-k\u00f3r klinikai megjelen\u00e9se, lefoly\u00e1sa, viselked\u00e9se\n                    rendk\u00edv\u00fcl v\u00e1ltozatos k\u00e9pet mutat, felismer\u00e9se a rendelkez\u00e9sre \u00e1ll\u00f3 eszk\u00f6z\u00f6k\n                    ellen\u00e9re is kih\u00edv\u00e1st jelenthet a nagy tapasztalattal b\u00edr\u00f3 klinikusok sz\u00e1m\u00e1ra is.\n                    Munk\u00e1nk c\u00e9lj\u00e1ul t\u0171zt\u00fck ki, hogy \u00f6sszefoglaljuk az Alzheimer-k\u00f3r genetikai,\n                    patol\u00f3giai \u00e9s klinikai jellemz\u0151it, seg\u00edtve ezzel a betegs\u00e9g jobb meg- \u00e9s\n                    felismer\u00e9s\u00e9t. Bemutatjuk a jelenleg \u00e9rv\u00e9nyben l\u00e9v\u0151 patol\u00f3giai \u00e9s klinikai\n                    ir\u00e1nyelvek krit\u00e9riumrendszereit, az \u00fajabb klasszifik\u00e1ci\u00f3s szeml\u00e9leteket.\n                    R\u00e9szletesen ismertetj\u00fck az Alzheimer-k\u00f3r heterogenit\u00e1s\u00e1t genot\u00edpus \u00e9s fenot\u00edpus\n                    szintj\u00e9n egyar\u00e1nt. Elemezz\u00fck a t\u00edpusos \u00e9s at\u00edpusos megjelen\u00e9si form\u00e1k\n                    jellemz\u0151it, a t\u00e1rsul\u00f3 k\u00f3r\u00e1llapotoknak a megjelen\u00e9sre \u00e9s a progresszi\u00f3ra\n                    gyakorolt hat\u00e1s\u00e1t. Orv Hetil. 2021; 162(25): 970\u2013977.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> Alzheimer\u2019s disease is the most prevalent neurodegenerative\n                    disorder. Morbidity and mortality of Alzheimer\u2019s disease are increasing\n                    worldwide causing important social and economic burden on the society. Over the\n                    past few decades, significant progress has been made in the understanding of the\n                    pathogenesis of Alzheimer\u2019s disease, several biomarkers support the diagnosis\n                    and drugs for symptomatic therapy had been introduced. The clinical\n                    manifestations and the course of Alzheimer\u2019s disease have a variable picture, so\n                    \u2013 despite the diagnostic opportunities \u2013 its diagnosis could be a challenge for\n                    highly experienced clinicians as well. The aim of our work was to summarize the\n                    genetic, pathological and clinical characteristics of Alzheimer\u2019s disease, thus\n                    helping to better understand and recognize the disease. We present the criteria\n                    systems of the currently valid pathological and clinical guidelines with the\n                    most recent classification approaches. The heterogeneity of Alzheimer\u2019s disease\n                    at both genotype and phenotype levels is described in detail. The\n                    characteristics of typical and atypical manifestations and the effect of\n                    co-pathologies on the appearance and progression of Alzheimer\u2019s disease are also\n                    discussed. Orv Hetil. 2021; 162(25): 970\u2013977.<\/jats:p>","DOI":"10.1556\/650.2021.32130","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:05:26Z","timestamp":1630404326000},"page":"970-977","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":4,"title":["Az Alzheimer-k\u00f3r heterogenit\u00e1sa"],"prefix":"10.1556","volume":"162","author":[{"given":"N\u00f3ra","family":"Bal\u00e1zs","sequence":"first","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Neurol\u00f3giai Klinika, Budapest, Balassa u. 6., 1083"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Kov\u00e1cs","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Neurol\u00f3giai Klinika, Budapest, Balassa u. 6., 1083"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2017.96","article-title":"A clinicopathological approach to the diagnosis of dementia","volume":"13","author":"Elahi FM","year":"2017","unstructured":"1 Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol. 2017; 13: 457-476.","journal-title":"Nat Rev Neurol"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2 Niu H, Alvarez-Alvarez I, Guillen-Grima F, et al. Trends of mortality from Alzheimer's disease in the European Union, 1994-2013. Eur J Neurol. 2017; 24: 858-866. [Erratum: Eur J Neurol. 2017; 24: 1200-1201.]","DOI":"10.1111\/ene.13302"},{"key":"ref2","unstructured":"3 Office for National Statistics. Deaths registered in England and Wales: 2019. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsregistrationsummarytables\/2019 [accessed: October 25, 2020]."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-010-0658-1","article-title":"Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics","volume":"119","author":"4 Kovacs","year":"2010","unstructured":"4 Kovacs GG, Botond G, Budka H. Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol. 2010; 119: 389-408.","journal-title":"Acta Neuropathol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Allegri RF. Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing \"where\" by \"what\"\u2026 Dement Neuropsychol. 2020; 14: 237-242.","DOI":"10.1590\/1980-57642020dn14-030005"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-010-0789-4","article-title":"The pathological process underlying Alzheimer's disease in individuals under thirty","volume":"121","author":"Braak H","year":"2011","unstructured":"6 Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011; 121: 171-181.","journal-title":"Acta Neuropathol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/01.wad.0000184005.22611.cc","article-title":"Early-stage and preclinical Alzheimer disease","volume":"19","author":"7 Morris","year":"2005","unstructured":"7 Morris JC. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord. 2005; 19: 163-165.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"8 Thal","year":"2002","unstructured":"8 Thal DR, R\u00fcb U, Orantes M, et al. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak H","year":"1991","unstructured":"9 Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-259.","journal-title":"Acta Neuropathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"10 Hyman","year":"2012","unstructured":"10 Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012; 8: 1-13.","journal-title":"Alzheimers Dement"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"Standardization of the neuropathologic assessment of Alzheimer's disease","volume":"41","author":"11 Mirra","year":"1991","unstructured":"11 Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack CR Jr","year":"2016","unstructured":"12 Jack CR Jr, Bennett DA, Blennow K, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016; 87: 539-547.","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack CR Jr","year":"2018","unstructured":"13 Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14: 535-562.","journal-title":"Alzheimers Dement"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"14 Shaw","year":"2009","unstructured":"14 Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65: 403-413.","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/\u03b2-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"15 Fagan","year":"2007","unstructured":"15 Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau\/\u03b2-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007; 64: 343-349.","journal-title":"Arch Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.neuroimage.2011.01.008","article-title":"Multimodal classification of Alzheimer's disease and mild cognitive impairment","volume":"55","author":"16 Zhang","year":"2011","unstructured":"16 Zhang D, Wang Y, Zhou L, et al. Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 2011; 55: 856-867.","journal-title":"Neuroimage"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.dadm.2017.06.001","article-title":"Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease","volume":"9","author":"17 Salloway","year":"2017","unstructured":"17 Salloway S, Gamez JE, Singh U, et al. Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimers Dement (Amst). 2017; 9: 25-34.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders","volume":"320","author":"18 Ossenkoppele","year":"2018","unstructured":"18 Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 2018; 320: 1151-1162.","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"19 Sperling","year":"2011","unstructured":"19 Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 280-292.","journal-title":"Alzheimers Dement"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"20 Albert","year":"2011","unstructured":"20 Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 270-279.","journal-title":"Alzheimers Dement"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"21 McKhann","year":"2011","unstructured":"21 McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 263-269.","journal-title":"Alzheimers Dement"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","article-title":"A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease","volume":"10","author":"22 Jessen","year":"2014","unstructured":"22 Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10: 844-852.","journal-title":"Alzheimers Dement"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23 Studart A Neto, Nitrini R. Subjective cognitive decline: the first clinical manifestation of Alzheimer's disease? Dement Neuropsychol. 2016; 10: 170-177.","DOI":"10.1590\/S1980-5764-2016DN1003002"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","article-title":"Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies","volume":"119","author":"24 Mitchell","year":"2009","unstructured":"24 Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009; 119: 252-265.","journal-title":"Acta Psychiatr Scand"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25 Cui Y, Liu B, Luo S, et al. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS ONE 2011; 6: e21896.","DOI":"10.1371\/journal.pone.0021896"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.neurobiolaging.2010.10.019","article-title":"Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance","volume":"33","author":"26 Ewers","year":"2012","unstructured":"26 Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012; 33: 1203-1214.","journal-title":"Neurobiol Aging"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000452486","article-title":"The risk of incident mild cognitive impairment and progression to dementia considering mild cognitive impairment subtypes","volume":"7","author":"27 Michaud","year":"2017","unstructured":"27 Michaud TL, Su D, Siahpush M, et al. The risk of incident mild cognitive impairment and progression to dementia considering mild cognitive impairment subtypes. Dement Geriatr Cogn Dis Extra 2017; 7: 15-29.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/archneur.59.11.1764","article-title":"Survival following a diagnosis of Alzheimer disease","volume":"59","author":"28 Brookmeyer","year":"2002","unstructured":"28 Brookmeyer R, Corrada MM, Curriero FC, et al. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002; 59: 1764-1767.","journal-title":"Arch Neurol"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29 Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018; 6: CD001190.","DOI":"10.1002\/14651858.CD001190.pub3"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/ene.12707","article-title":"EFNS-ENS\/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease","volume":"22","author":"30 Schmidt","year":"2015","unstructured":"30 Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS\/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 2015; 22: 889-898.","journal-title":"Eur J Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00002093-199903000-00006","article-title":"Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease","volume":"13","author":"31 Tounsi","year":"1999","unstructured":"31 Tounsi H, Deweer B, Ergis AM, et al. Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease. Alzheimer Dis Assoc Disord. 1999; 13: 38-46.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt155","article-title":"Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome","volume":"5","author":"32 Lam","year":"2013","unstructured":"32 Lam B, Masellis M, Freedman M, et al. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimers Res Ther. 2013; 5: 1.","journal-title":"Alzheimers Res Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1017\/S1355617711001287","article-title":"Probable Alzheimer's disease patients presenting as \"focal temporal lobe dysfunction\" show a slow rate of cognitive decline","volume":"18","author":"33 Marra","year":"2012","unstructured":"33 Marra C, Villa G, Quaranta D, et al. Probable Alzheimer's disease patients presenting as \"focal temporal lobe dysfunction\" show a slow rate of cognitive decline. J Int Neuropsychol Soc. 2012; 18: 144-150.","journal-title":"J Int Neuropsychol Soc"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/jnnp.70.1.22","article-title":"Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment","volume":"70","author":"34 Cappa","year":"2001","unstructured":"34 Cappa A, Calcagni ML, Villa G, et al. Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment. J Neurol Neurosurg Psychiatry 2001; 70: 22-27.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2018.07.215","article-title":"Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease","volume":"15","author":"35 Bell","year":"2019","unstructured":"35 Bell WR, An Y, Kageyama Y, et al. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease. Alzheimers Dement. 2019; 15: 8-16.","journal-title":"Alzheimers Dement"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1093\/brain\/awv191","article-title":"The behavioural\/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features","volume":"138","author":"36 Ossenkoppele","year":"2015","unstructured":"36 Ossenkoppele R, Pijnenburg YA, Perry DC, et al. The behavioural\/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain 2015; 138: 2732-2749.","journal-title":"Brain"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","article-title":"Consensus classification of posterior cortical atrophy","volume":"13","author":"37 Crutch","year":"2017","unstructured":"37 Crutch SJ, Schott JM, Rabinovici GD, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017; 13: 870-884.","journal-title":"Alzheimers Dement"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"38 Gorno-Tempini","year":"2011","unstructured":"38 Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014.","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1212\/WNL.0000000000001831","article-title":"Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study","volume":"85","author":"39 Kawas","year":"2015","unstructured":"39 Kawas CH, Kim RC, Sonnen JA, et al. Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology 2015; 85: 535-542.","journal-title":"Neurology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.trci.2016.09.002","article-title":"Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development","volume":"3","author":"40 Rabinovici","year":"2017","unstructured":"40 Rabinovici GD, Carrillo MC, Forman M, et al. Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimers Dement (N Y). 2017; 3: 83-91.","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","article-title":"Impact of multiple pathologies on the threshold for clinically overt dementia","volume":"134","author":"41 Kapasi","year":"2017","unstructured":"41 Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017; 134: 171-186.","journal-title":"Acta Neuropathol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"42 Outeiro","year":"2019","unstructured":"42 Outeiro TF, Koss DJ, Erskine D, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019; 14: 5.","journal-title":"Mol Neurodegener"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","article-title":"Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study","volume":"10","author":"43 Murray","year":"2011","unstructured":"43 Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011; 10: 785-796.","journal-title":"Lancet Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000278692","article-title":"Clinical features of rapidly progressive Alzheimer's disease","volume":"29","author":"44 Schmidt","year":"2010","unstructured":"44 Schmidt C, Redyk K, Meissner B, et al. Clinical features of rapidly progressive Alzheimer's disease. Dement Geriatr Cogn Disord. 2010; 29: 371-378.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1017\/S0317167100013949","article-title":"Early-onset familial Alzheimer's disease (EOFAD)","volume":"39","author":"45 Wu","year":"2012","unstructured":"45 Wu L, Rosa-Neto P, Hsiung GY, et al. Early-onset familial Alzheimer's disease (EOFAD). Can J Neurol Sci. 2012; 39: 436-445.","journal-title":"Can J Neurol Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2147\/CIA.S51571","article-title":"The genetics of Alzheimer's disease","volume":"9","author":"46 Bagyinszky","year":"2014","unstructured":"46 Bagyinszky E, Youn YC, An SS, et al. The genetics of Alzheimer's disease. Clin Interv Aging 2014; 9: 535-551.","journal-title":"Clin Interv Aging"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1474-4422(16)30229-0","article-title":"Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)","volume":"15","author":"47 Tang","year":"2016","unstructured":"47 Tang M, Ryman DC, McDade E, et al. Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 2016; 15: 1317-1325.","journal-title":"Lancet Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.trci.2017.08.009","article-title":"Toward common mechanisms for risk factors in Alzheimer's syndrome","volume":"3","author":"48 Medina","year":"2017","unstructured":"48 Medina M, Khachaturian ZS, Rossor M, et al. Toward common mechanisms for risk factors in Alzheimer's syndrome. Alzheimers Dement (N Y). 2017; 3: 571-578.","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/joim.12192","article-title":"Pathways to Alzheimer's disease","volume":"275","author":"49 Hardy","year":"2014","unstructured":"49 Hardy J, Bogdanovic N, Winblad B, et al. Pathways to Alzheimer's disease. J Intern Med. 2014; 275: 296-303.","journal-title":"J Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"50 Liu","year":"2013","unstructured":"50 Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9: 106-118.","journal-title":"Nat Rev Neurol"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/25\/article-p970.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/25\/article-p970.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T08:38:31Z","timestamp":1698741511000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/25\/article-p970.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,20]]},"references-count":50,"journal-issue":{"issue":"25"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32130","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,20]]}}}